Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.

ABSTRACT:

SUBMITTER: Tweed CD 

PROVIDER: S-EPMC7641992 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature